The abstract is read at the publisher; the summary is JClub's.
LZK inhibition suppresses AKT activation and limits tumor growth in MAP3K13-amplified esophageal squamous cell carcinoma xenografts, with AKT phosphorylation at S473/T450 reduced.
- Why it matters: ESCC and head and neck squamous cell carcinoma lack clear oncogenic drivers, and MAP3K13-amplified tumors need targeted vulnerabilities beyond current treatment options.
- What they did: The study tested a newly described LZK catalytic inhibitor and GNE-3511 in MAP3K13-amplified ESCC and HNSCC models, measuring viability, AKT activation, and LZK–AKT binding.
- The result: LZK inhibition decreased ESCC cell viability and suppressed tumor growth in MAP3K13-amplified patient-derived xenograft mice, and AKT activation was rescued by a LZK drug-resistant mutant, supporting LZK-mediated AKT scaffolding.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.